European-approved cholesterol drug obicetrapib reduced Alzheimer's biomarkers in carriers of two ApoE4 gene copies, a group facing nearly tenfold the average dementia risk

European-approved cholesterol drug obicetrapib reduced Alzheimer's biomarkers in carriers of two ApoE4 gene copies, a group facing nearly tenfold the average dementia risk

On September 21, the European Commission approved obicetrapib for high cholesterol, the first drug in its class to reach the market after four predecessors failed. In the same BROADWAY trial, the drug's effect on blood-based Alzheimer's markers was separately assessed in 1535 participants. The strongest response appeared in 29 people carrying two copies of the ApoE4 gene, for whom no approved method of dementia prevention currently exists.

Obicetrapib blocks CETP, a protein that transfers cholesterol from "good" HDL particles to "bad" LDL particles in the blood. By keeping cholesterol in HDL, the drug helps the liver clear LDL more efficiently: in BROADWAY, LDL levels fell by nearly 30%, while HDL more than doubled. People who carry naturally low-activity variants of the CETP gene have a 72% lower observed risk of dementia, which serves as independent confirmation that CETP is the right target. Cholesterol transport within the brain is handled by a different gene, ApoE; the E4 variant performs this job less effectively than others, causing amyloid, a protein aggregate considered one of the causes of Alzheimer's disease, to accumulate faster. One copy of E4 raises disease risk roughly threefold; two copies raise it roughly tenfold.

Among 1535 BROADWAY participants with known ApoE status, the change in p-tau217, the leading blood-based Alzheimer's marker, was compared over one year of treatment. In ApoE4 carriers, the marker rose by 1.9% on the drug versus 6.9% on placebo. In the 29 individuals with two E4 copies, it fell by 7.8% versus a 12.7% rise on placebo: a difference of nearly 20.5 percentage points. In the same group, GFAP and NfL, markers of brain inflammation and neuronal damage, also declined; the higher the drug concentration in the blood, the greater the reduction. The link from blood to brain is so far explained only by a hypothesis: HDL particles can cross the blood-brain barrier and remove excess cholesterol from neurons, partly compensating for ApoE4's poor performance.

Biotech entrepreneur Nathaniel David, co-founder of the anti-aging startup Unity Biotechnology, wrote about this on X. He recalled the history of the class: in 2006, the first CETP inhibitor, torcetrapib, killed patients by sharply raising their blood pressure, and Pfizer halted the trial early; two more drugs showed no clinical benefit, and a fourth accumulated in adipose tissue for years and never reached the market. Obicetrapib has already completed a Phase III trial with more than 3000 patients: its side-effect rates did not exceed those of placebo.

Jessica Langbaum, director of Alzheimer's prevention at Banner Alzheimer's Institute, believes a drug like this could meaningfully reduce the burden of dementia. Because BROADWAY enrolled cardiac patients rather than healthy ApoE4 carriers, a separate prevention trial of obicetrapib specifically for high-risk ApoE4 carriers is already being planned on the basis of these data.

Menarini, the Italian company that holds the exclusive European sales rights to obicetrapib, is preparing the first sales in Germany and the United Kingdom before the end of 2026, ahead of the results of that trial. Once the drug reaches pharmacies, it will be available as a standard cholesterol medication, with a chance of protecting the brain as well.